Pfizer has asked the FDA to authorize extra-low doses of its COVID-19 vaccine for children ages 6 months through 4 years.
The FDA will review the application and convene a panel of outside advisors in mid-February to debate the data latimes.com/science/story/…
The FDA will review the application and convene a panel of outside advisors in mid-February to debate the data latimes.com/science/story/…
Shots for children in this age group are one-tenth the size of the adult doses.
Pfizer will have to specially bottle the extra-low doses so vaccine providers don’t mix them up with the two other dosages already being used latimes.com/science/story/…
Pfizer will have to specially bottle the extra-low doses so vaccine providers don’t mix them up with the two other dosages already being used latimes.com/science/story/…
Pfizer previously said study results showed two of the extra-low doses appeared strong enough to protect babies but weren’t strong enough for 2- to 4-year-olds.
The company added a third shot to the study, but results are not expected until late March latimes.com/science/story/…
The company added a third shot to the study, but results are not expected until late March latimes.com/science/story/…
COVID-19 vaccines for kids younger than 5 may be available in the U.S. as early as March.
But there are several hurdles still left to clear: latimes.com/science/story/…
But there are several hurdles still left to clear: latimes.com/science/story/…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
